top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.8854 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
36 37 Next >
News headline image
Ocugen Still Lacks a Path to U.S. Profits ↗
Ocugen still lacks a proper catalyst and nothing has changed for it. As a result, investors should avoid OCGN stock. 
Via InvestorPlace
News headline image
Ocugen, Inc. (NASDAQ:OCGN) Long Term Investor Alert: Investigation of Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 09/28/2021 -- Certain directors of Ocugen, Inc are under investigation concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc. 
Via SBWire
Topics Lawsuit
News headline image
Ocugen-Partnered Covaxin's WHO Clearance Delayed Further Over Queries: Sources ↗
The World Health Organization (WHO) has further delayed the emergency use authorization (EUA) for Covaxin, a COVID-19 vaccine developed in India. Ocugen Inc (NASDAQ:... 
Via Benzinga
News headline image
Is Ocugen Worth Another Look After Good News for COVID Vaccine Covaxin? ↗
An anticipated emergency use listing for the vaccine won't help Ocugen. 
Via The Motley Fool
News headline image
Ocugen's India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report ↗
India-based Bharat Biotech has completed the Phase 2 and 3 trials of COVID-19 vaccine, Covaxin, for use in 2 to 18 years. Ocugen Inc (NASDAQ: OCGN... 
Via Benzinga
News headline image
It’s OK to Sell the News on Ocugen and Covaxin ↗
OCGN stock jumped when Covaxin received WHO approval. But with two major obstacles in the way of U,S. approval, you should sell the news. 
Via InvestorPlace
News headline image
Could This News Spark a Turnaround for Ocugen? ↗
Ocugen shares soared more than 700% early in the year. They've since lost half of the gain. 
Via The Motley Fool
News headline image
Why COVID Vaccine Stocks BioNTech, Moderna, and Novavax Are Sliding While Ocugen Is Rising ↗
Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision. 
Via The Motley Fool
News headline image
I’d Take Nio Stock’s 12-Month Double Despite Falling Below $50 ↗
A $10,000 investment in NIO stock a year ago is worth more than $20,000 today. From here, under $40 remains a great entry point if you want to make money over the long haul. 
Via InvestorPlace
Topics Electric Vehicles
News headline image
WHO Approval Should Get Ocugen Stock Over the $15 Barrier ↗
Sharp up-and-down moves in OCGN stock shouldn't scare investors away, as a regulator's nod for Covaxin should put the stock back on track. 
Via InvestorPlace
News headline image
Here’s What the Charts Say About Ocugen Stock Now ↗
Ocugen is a high-risk, high-reward speculative play. The charts for OCGN stock show some promise, but here's the level it has to hold above. 
Via InvestorPlace
News headline image
72 Biggest Movers From Yesterday ↗
Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead... 
Via Benzinga
News headline image
OCGN Stock: Why Ocugen Shares Are Shooting Higher Today ↗
The WHO could be about to green light a vaccine from one of Ocugen's partners, but that doesn't mean OCGN stock will stay in the green. 
Via InvestorPlace
News headline image
Where's Ocugen Stock Headed Monday And Why? ↗
Ocugen Inc. (NASDAQ: OCGN) shares were trading higher Monday, after Bharat Biotech: a company partner, was given the nod for a COVID-19 vaccine by the World Health Organization.... 
Via Benzinga
News headline image
Here's Why Ocugen Is Skyrocketing Today ↗
There's both good and bad news for this troubled coronavirus vaccine biotech. 
Via The Motley Fool
News headline image
OCGN Stock: What Ocugen Investors Are Saying as Shares Surge Today ↗
Ocugen (OCGN) stock is on the move today as traders on social media push the company higher in a new rally for the shares. 
Via InvestorPlace
News headline image
Why Are Ocugen Shares Surging On Monday? ↗
According to sources, the World Health Organization (WHO) is likely to grant India's COVID-19 vaccine, Covaxin, for an emergency use listing (EUL) this week. Ocugen Inc... 
Via Benzinga
News headline image
45 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets. Itamar Medical Ltd. (NASDAQ: ITMR)... 
Via Benzinga
News headline image
OCUGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ocugen, Inc. - OCGN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Vaxart Stock Is One Vaccine Also-Ran Worth Another Look ↗
The jury's out whether its oral Covid-19 vaccine will be successful, but VXRT stock may still be worth it as a speculative play. 
Via InvestorPlace
News headline image
This 28% Short Biotech Company Has A Better 1-Year Return Than AMC, Snap, Apple And Tesla ↗
An investment in Ocugen Inc (NASDAQ: OCGN) one year ago is undoubtedly a sight for sore eyes. Since January 2021, Ocugen stock's year-to-date return has outperformed a number... 
Via Benzinga
News headline image
Ocugen Should Hit $9 If Its Covid-19 Vaccine Gets Approved ↗
There's no revenue yet for Ocugen, but OCGN stock could be worth 19% higher if its Covid-19 vaccine gets the thumbs up. 
Via InvestorPlace
News headline image
Ocugen Stock Will Suffer Its Inevitable Demise Sooner Rather Than Later ↗
At some point, the music will stop for OCGN stock, but for now, there's still plenty at play to keep it at inflated prices. 
Via InvestorPlace
News headline image
Ocugen Stock Seems Unattractive With Regulatory Uncertainties ↗
OCGN stock is unattractive as regulatory approval delays have limited the revenue and cash flow potential for the Covid-19 vaccine. 
Via InvestorPlace
News headline image
Ocugen Stock Doesn’t Have Short-Term Catalysts Needed To Make It a Buy ↗
OCGN stock is interesting once again as concerns regarding the Delta variant mount. But that should not be your sole reason to invest in Ocugen. 
Via InvestorPlace
News headline image
Atossa Therapeutics May Look Tempting, but There’s No Reason to Get in Now ↗
ATOS stock has some exciting points, but its story sends a message investors have heard, namely the price of progress is dilution. 
Via InvestorPlace
News headline image
The Odds Are Firmly Against Ocugen Stock Now ↗
OCGN stock is a remarkably risky Covid-19 vaccine play, as the company faces a myriad of regulatory roadblocks on different fronts. 
Via InvestorPlace
News headline image
2 Popular Robinhood Stocks I Wouldn't Buy With Free Money ↗
Not every stock on the popular trading app is worth owning. 
Via The Motley Fool
News headline image
Vaccine Victory ↗
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson... 
Via Talk Markets
Topics Economy
News headline image
Cynicism and Conspiracy Theories Could Help Ocugen ↗
While OCGN stock seems well behind the vaccination race to be worth a shot, there is one narrative that could potentially help. 
Via InvestorPlace
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page